Trial Profile
A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2021
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shire
- 26 Nov 2021 Results assessing the pharmacokinetics, safety, and tolerability of SHP465 mixed amphetamine salts (MAS) 6.25 mg after multiple once-daily doses in children aged 4-5 years with attention-deficit/hyperactivity disorder, published in the CNS Drugs.
- 02 Jan 2019 Status changed from recruiting to completed.
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.